RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more
RHYTHM Biosciences Ltd (RHY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -1.037x
Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) has a cash flow conversion efficiency ratio of -1.037x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.22 Million) by net assets (AU$2.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RHYTHM Biosciences Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how RHYTHM Biosciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
RHYTHM Biosciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RHYTHM Biosciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Generations Bancorp NY Inc
NASDAQ:GBNY
|
0.046x |
|
LOOP INDUSTRIES DL-001
F:3L9
|
N/A |
|
QES Group Bhd
KLSE:0196
|
0.036x |
|
TUBOS REUNIDOS A EO -02
F:TU1
|
N/A |
|
Ping Ho Environmental Technology Co., Ltd.
TW:6771
|
0.061x |
|
Econpile Holdings Bhd
KLSE:5253
|
0.006x |
|
Ballston Spa Bancorp Inc
PINK:BSPA
|
0.043x |
|
Heidelberg Pharma AG
F:HPHA
|
-0.299x |
Annual Cash Flow Conversion Efficiency for RHYTHM Biosciences Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of RHYTHM Biosciences Ltd from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$659.89K | AU$-2.92 Million | -4.427x | +37.45% |
| 2024-06-30 | AU$867.17K | AU$-6.14 Million | -7.077x | -497.55% |
| 2023-06-30 | AU$5.87 Million | AU$-6.96 Million | -1.184x | -40.49% |
| 2022-06-30 | AU$7.37 Million | AU$-6.21 Million | -0.843x | +73.37% |
| 2021-06-30 | AU$1.71 Million | AU$-5.40 Million | -3.165x | -112.71% |
| 2020-06-30 | AU$1.84 Million | AU$-2.74 Million | -1.488x | -195.92% |
| 2019-06-30 | AU$5.85 Million | AU$-2.94 Million | -0.503x | -152.79% |
| 2018-06-30 | AU$8.30 Million | AU$-1.65 Million | -0.199x | -2177166.56% |
| 2017-06-30 | AU$1.42 Million | AU$-13.00 | 0.000x | -- |